Boston Scientific and Blackstone Life Sciences will share $455 million to help develop the Vitalyst heart pump.

Nov 2, 2026, 10:11 PM ETDealRead the original at morningstar.com

Good for BSX

Boston Scientific secured $455 million in shared funding to develop its Vitalyst heart pump. The device's expected benefits have not been shown yet, but the new development funding makes this favorable for the company.

BSX · Boston Scientific

AI read · Good for BSX

The AI's read

The funding gives Boston Scientific a partner to help move Vitalyst through development. The device is still being developed, so its expected safety and effectiveness gains have not been shown. The funding support is the clearest change for the company.

Get alerts for BSX

Follow Boston Scientific (BSX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BSX

Free on the App Store and Google Play, or on the web.